Related Experiment Video
Updated: Apr 7, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
A Novel Approach to Treating Adults With Type 1 Diabetes and Recurrent Diabetic Ketoacidosis: Once-Daily Subcutaneous
Jaspreet Batth1, Benjamin Langworthy2, Anjali Kumar1
1Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota.
Objective:
We assessed the impact of adding subcutaneous basal insulin to hybrid closed-loop insulin pump therapy on diabetic ketoacidosis (DKA) rates and glycemic outcomes in adults with type 1 diabetes (T1D) and recurrent DKA.
Methods:
We conducted a retrospective review of electronic health records from adults with T1D and recurrent DKA who received concurrent treatment with subcutaneous basal insulin and hybrid closed-loop insulin pump therapy at an academic health system in the United States. We performed an as-treated analysis using descriptive statistics.
Results:
Our cohort included 5 adults (3 women, 2 men; mean age 39.4 ± 10.8 years) with T1D and recurrent DKA. Due to elevated DKA risk, all 5 adults were initiated on once-daily subcutaneous basal insulin (degludec or glargine, mean dose 0.14 units/kg/d, range 0.07-0.22 units/kg/d) in addition to insulin pump therapy (Omnipod 5 with automated insulin delivery). Mean HbA1c decreased from 9.3% (79 mmol/mol) (days -360 to -1) to 8.2% (66 mmol/mol) (days 0 to 360) following the intervention. The frequency of DKA-related hospitalizations decreased from a mean of 2.0 events per person (days -360 to -1) to 0.75 events per person (days 0 to 360). One individual discontinued subcutaneous basal insulin due to recurrent level 1 hypoglycemia.
Conclusion:
Adding once-daily subcutaneous basal insulin to hybrid closed-loop therapy may have the potential to reduce DKA-related hospitalizations and improve glycemic outcomes in adults with T1D and recurrent DKA. However, given this was a retrospective study with a small cohort, further research is needed to rigorously evaluate this approach.
More Related Videos
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Symptoms, Diagnosis, and Complications

